DE602004025328D1 - Hypoxie-induzierbares vegf plasmid für ischämische erkrankung - Google Patents

Hypoxie-induzierbares vegf plasmid für ischämische erkrankung

Info

Publication number
DE602004025328D1
DE602004025328D1 DE602004025328T DE602004025328T DE602004025328D1 DE 602004025328 D1 DE602004025328 D1 DE 602004025328D1 DE 602004025328 T DE602004025328 T DE 602004025328T DE 602004025328 T DE602004025328 T DE 602004025328T DE 602004025328 D1 DE602004025328 D1 DE 602004025328D1
Authority
DE
Germany
Prior art keywords
hypoxia
plasmids
treating ischemic
pharmaceutical compositions
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004025328T
Other languages
German (de)
English (en)
Inventor
Minhyung Lee
Sung Wan Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of DE602004025328D1 publication Critical patent/DE602004025328D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE602004025328T 2003-02-21 2004-02-23 Hypoxie-induzierbares vegf plasmid für ischämische erkrankung Expired - Lifetime DE602004025328D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44896103P 2003-02-21 2003-02-21
PCT/US2004/005372 WO2004076633A2 (en) 2003-02-21 2004-02-23 Hypoxia inducible vegf plasmid for ischemic disease

Publications (1)

Publication Number Publication Date
DE602004025328D1 true DE602004025328D1 (de) 2010-03-18

Family

ID=32927484

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025328T Expired - Lifetime DE602004025328D1 (de) 2003-02-21 2004-02-23 Hypoxie-induzierbares vegf plasmid für ischämische erkrankung

Country Status (9)

Country Link
US (2) US7638322B2 (cg-RX-API-DMAC7.html)
EP (1) EP1594549B1 (cg-RX-API-DMAC7.html)
JP (1) JP4652325B2 (cg-RX-API-DMAC7.html)
KR (1) KR101077689B1 (cg-RX-API-DMAC7.html)
AT (1) ATE456380T1 (cg-RX-API-DMAC7.html)
CA (1) CA2516727C (cg-RX-API-DMAC7.html)
DE (1) DE602004025328D1 (cg-RX-API-DMAC7.html)
ES (1) ES2339113T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004076633A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553162A (en) 2004-08-16 2010-03-26 Quark Biotech Inc Double stranded siRNA compounds that inhibit RRTP801
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
WO2008106102A2 (en) 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US6548633B1 (en) * 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides

Also Published As

Publication number Publication date
WO2004076633A3 (en) 2005-06-02
ATE456380T1 (de) 2010-02-15
US7638322B2 (en) 2009-12-29
US20110015257A1 (en) 2011-01-20
EP1594549B1 (en) 2010-01-27
JP2006518604A (ja) 2006-08-17
JP4652325B2 (ja) 2011-03-16
CA2516727A1 (en) 2004-09-10
EP1594549A4 (en) 2008-01-23
KR101077689B1 (ko) 2011-10-27
ES2339113T3 (es) 2010-05-17
CA2516727C (en) 2014-02-04
WO2004076633A2 (en) 2004-09-10
US7998941B2 (en) 2011-08-16
EP1594549A2 (en) 2005-11-16
KR20050103302A (ko) 2005-10-28
US20070149467A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
Kleinman et al. Thymosin β4 promotes dermal healing
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
NO20051575L (no) Bruk av quinazolinderivatet ZD6474 i kombinasjon med gemcitabin og valgfritt ioniserende straling i behandling av sykdommer forbundet med angiogenese og/eller okt kar-gjennomtrengelighet
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
RU95120403A (ru) Стимулятор эндогенной продукции цитокинов и гемопоэтических факторов и способ его использования
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE553772T1 (de) Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel
JP2014530873A5 (cg-RX-API-DMAC7.html)
JP2012522762A5 (cg-RX-API-DMAC7.html)
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
NZ515891A (en) New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
GEAP202516706A (en) Cyclic peptides for trapping interleukin-1 beta
JP2010538020A5 (cg-RX-API-DMAC7.html)
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
EP1594549A4 (en) VEGF INDUCIBLE PLASMID FOR HYPOXIA USEFUL IN TREATING ISCHEMIC DISEASE
NO20055692L (no) Intravenos injeksjon av ikkeneurotoksiske plasminogenaktivatorer til behandling av cerebralt slag
WO2004004664A3 (en) Methods for treating or preventing ischemic injury
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
JP2014512369A5 (cg-RX-API-DMAC7.html)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
Crossman et al. Bradykinin induced wheal and flare is not mediated by histamine release or cyclooxygenase products.
DE602005013542D1 (de) Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18

Legal Events

Date Code Title Description
8364 No opposition during term of opposition